EGFR and colorectal carcinoma: In conclusion, acquired RAS and BRAF genetic alterations have been identified as a mechanism of acquired resistance to anti-EGFR therapy in CRC and these genetic alterations most likely arise because of clonal selection of pre-existing resistant cells.